<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                             September 13, 2024

David Quek Yong Qi
Chief Executive Officer
Cuprina Holdings (Cayman) Limited
Blk 1090 Lower Delta Road #06-08
Singapore 169201

       Re: Cuprina Holdings (Cayman) Limited
           Amendment No. 6 to Registration Statement on Form F-1
           Filed September 9, 2024
           File No. 333-277731
Dear David Quek Yong Qi:

     We have reviewed your amended registration statement and have the
following
comments.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe a comment applies to your facts
and circumstances
or do not believe an amendment is appropriate, please tell us why in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this letter, we may have additional comments.

Amendment No. 6 to Registration Statement on Form F-1
Prospectus Summary
Corporate History and Structure, page 7

1.     Please revise the chart in this section and on page 53 to show the
post-offering ownership
       percentages.
Business
Licenses, Permits, Registrations and Approvals, page 103

2.     Your disclosure on page 104 indicates that your Hong Kong import permit
has expired.
       Please revise to clarify the status of this permit.
Underwriting, page 160

3.     We note your disclosure that the underwriters will offer selected
dealers shares at the
       initial public offering price less a selling concession not in excess of
US$4.50 per share.
 September 13, 2024
Page 2

       We further note that the offering price per share to the public is
between US$4.00 and
       US$4.50 per share. Please revise your disclosure or advise.
General

4.     Please revise the legal opinion filed as Exhibit 5.1 to quantify the
number of shares and
       warrants being registered.
       Please contact Christine Torney at 202-551-3652 or Angela Connell at
202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Doris Stacey Gama at 202-551-3188 or Alan Campbell at 202-551-4224 with
any other
questions.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Lawrence Venick, Esq.
</TEXT>
</DOCUMENT>
